Why do some studies find a benefit and others do not?
The mixed findings partly reflect what blue light is being compared against. A 2022 meta-analysis of nine randomized controlled trials found no evidence that blue-light therapy outperformed inactive light conditions, but it also found no difference between blue light and active light conditions [4]. In other words, blue light may look ineffective when the comparison is a sham treatment, yet indistinguishable from another active light treatment—suggesting that the specific color may not be the key ingredient, or that the studies were too small or too different to detect a real effect.
An earlier study using narrow-band LED panels did report that blue-light therapy appeared effective for SAD [3]. That positive result, set against the later meta-analysis, illustrates how conclusions can shift with the pool of trials included. The meta-analysis itself concluded that the efficacy of blue-light therapy remains unproven and called for better standardization of light therapy parameters [4].
Do illuminance and exposure duration explain the inconsistency?
Illuminance—the intensity of light, measured in lux—and exposure duration are standard variables in light therapy, and general treatment guidance recommends around 10,000 lux for 30 to 60 minutes daily [1]. But the blue-light meta-analysis did not analyze how illuminance or exposure duration influenced outcomes [4], so it cannot tell us whether these parameters account for the divergent findings. The narrow-band blue-light study also did not address variations in illuminance or duration [3].
A rodent study offers a clue that duration and intensity matter biologically: in diurnal grass rats housed under dim winter-like light, daily one-hour early-morning bright light therapy (10,000 lux) altered markers of neuroinflammation and neuroplasticity in brain regions involved in mood and cognition, with effects differing between males and females [5]. This suggests that the therapeutic effects of bright light may involve these markers, but it does not establish that illuminance or duration explain the human study inconsistencies.
Does short-term blue light exposure change the retina in a way that could affect treatment?
One study examined whether blue light exposure in the two hours before testing influenced retinal responsivity—how the pupil responds to light after a stimulus—in people with SAD and in controls. It found that short-term blue-light exposure did not significantly predict retinal responsivity in either group [2]. This is relevant because retinal responsivity is lower in SAD during winter and may contribute to the seasonal mood pattern, but the study did not test therapeutic effects, so it cannot say whether short-term exposure helps or hinders treatment.
The same study noted that future work should evaluate different light exposure parameters, such as longer durations or different timeframes [2]. That points to a gap: the parameters that might explain inconsistent treatment results have not been systematically tested in the blue-light trials summarized so far.
What else could account for the mixed findings?
Beyond illuminance and duration, the meta-analysis pointed to trial characteristics: it called for longer-duration trials, larger sample sizes, and better standardization of light therapy parameters [4]. Those are signs that the existing studies may be too small or too varied to give a stable answer. The rodent work adds another layer—effects on neuroinflammatory and neuroplasticity markers differed by sex [5]—raising the possibility that individual biological differences, not just light dose, shape who responds.
General descriptions of light therapy also note that the therapeutic benefit appears to require the eyes and light-activated pathways, since light applied to the back of the knee had no effect on SAD symptoms [1]. That supports a biological mechanism tied to the retina and circadian system, but it does not resolve why some blue-light trials succeed and others fail. The honest answer is that illuminance and duration are reasonable suspects, but the evidence has not yet shown they are the deciding factor.
Sources used in this answer
Light therapy for seasonal affective disorder: correspondence
This correspondence reviews general light therapy principles for SAD, including recommended illuminance (10,000 lux) and exposure duration (30–60 minutes daily), and notes that light applied to the knee had no effect, suggesting the eyes are required.
0653 The effects of light exposure on retinal responsivity in seasonal affective disorder
In a study of 17 people with SAD and 19 controls, blue light exposure in the two hours before testing did not significantly predict retinal responsivity in either group.
Narrow‐band blue‐light treatment of seasonal affective disorder in adults and the influence of additional nonseasonal symptoms
Narrow-band blue-light therapy using LED panels appeared to be an effective treatment for SAD in adults, compared with red-light placebo.
Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
A meta-analysis of nine randomized controlled trials found no evidence that blue-light therapy was efficacious compared with inactive conditions, and no difference compared with active conditions, for seasonal and non-seasonal depression.
Effects of bright light therapy on neuroinflammatory and neuroplasticity markers in a diurnal rodent model of Seasonal Affective Disorder
In a diurnal rodent model of SAD, four weeks of daily one-hour early-morning bright light therapy altered neuroinflammatory and neuroplasticity markers in mood-related brain regions, with effects varying between males and females.